What is N-Acetyl Semax Amidate?

A modified Semax with an acetyl cap and an amide end, sold as a longer-lasting version; human data exist only for regular Semax.

N-Acetyl Semax Amidate in the library · · Human Trials · What are peptides?

0 registered trials · 0 indexed papers · 1 human / 5 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

N-Acetyl Semax Amidate is described as Semax (an ACTH(4-10)-derived heptapeptide used in Russia) with an acetyl group on one end and an amide on the other. Plain Semax has its own page.

The modifications are intended to slow breakdown by enzymes.

Mechanism (as described)

  • Lab work shows N-terminal acetylation makes Semax more resistant to proteolysis in biological fluids (Shevchenko et al., 2013) and changes how it binds copper and zinc (Magrì et al., 2016).

Evidence (as described)

  • No human trial of the acetylated amidated form is on file. Clinical use in Russia is of regular Semax nasal drops.

Status

Not approved anywhere (regular Semax is registered in Russia).

More cited research

Related compounds

FAQ

What is N-Acetyl Semax Amidate?

A modified Semax with an acetyl cap and an amide end, sold as a longer-lasting version; human data exist only for regular Semax.

How many registered human trials study N-Acetyl Semax Amidate?

The PeptideWhiz trial index lists 0 registered trials for N-Acetyl Semax Amidate.

How much published research exists on N-Acetyl Semax Amidate?

By study type, PeptideWhiz counts 1 human and 5 animal studies on N-Acetyl Semax Amidate.

Which conditions is N-Acetyl Semax Amidate researched for?

No condition pages are linked to this compound yet.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).